CY2287B1 - Farnesyl transferase inhibiting 2-quinolone derivatives - Google Patents

Farnesyl transferase inhibiting 2-quinolone derivatives

Info

Publication number
CY2287B1
CY2287B1 CY0200044A CY0200044A CY2287B1 CY 2287 B1 CY2287 B1 CY 2287B1 CY 0200044 A CY0200044 A CY 0200044A CY 0200044 A CY0200044 A CY 0200044A CY 2287 B1 CY2287 B1 CY 2287B1
Authority
CY
Cyprus
Prior art keywords
farnesyl transferase
quinolone derivatives
transferase inhibiting
inhibiting
quinolone
Prior art date
Application number
CY0200044A
Other languages
English (en)
Inventor
David William Venet Marc G End
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY2287B1 publication Critical patent/CY2287B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY0200044A 1995-10-31 2002-07-15 Farnesyl transferase inhibiting 2-quinolone derivatives CY2287B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202945 1995-10-31

Publications (1)

Publication Number Publication Date
CY2287B1 true CY2287B1 (en) 2003-07-04

Family

ID=8220785

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0200044A CY2287B1 (en) 1995-10-31 2002-07-15 Farnesyl transferase inhibiting 2-quinolone derivatives

Country Status (29)

Country Link
US (1) US5968952A (xx)
EP (2) EP1019395B1 (xx)
JP (1) JP4257869B2 (xx)
KR (1) KR100417620B1 (xx)
CN (1) CN1101391C (xx)
AR (1) AR004699A1 (xx)
AT (2) ATE269322T1 (xx)
AU (1) AU712435B2 (xx)
CA (1) CA2231143C (xx)
CY (1) CY2287B1 (xx)
CZ (1) CZ290954B6 (xx)
DE (2) DE69632751T2 (xx)
DK (1) DK1019395T3 (xx)
EA (1) EA000719B1 (xx)
ES (2) ES2233557T3 (xx)
HK (2) HK1027576A1 (xx)
HU (1) HU224032B1 (xx)
IL (1) IL123567A (xx)
MY (1) MY116577A (xx)
NO (1) NO314037B1 (xx)
NZ (1) NZ321576A (xx)
PL (1) PL184168B1 (xx)
PT (1) PT1019395E (xx)
SI (1) SI1019395T1 (xx)
SK (1) SK282642B6 (xx)
TR (1) TR199800720T2 (xx)
TW (1) TW349948B (xx)
WO (1) WO1997016443A1 (xx)
ZA (1) ZA969087B (xx)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4209472B2 (ja) 1997-06-02 2009-01-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 平滑筋細胞増殖のインヒビターとしての（イミダゾール−５−イル）メチル−２−キノリノン誘導体
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CA2312720A1 (en) 1997-12-11 1999-06-17 Janssen-Cilag S.A. Retinoic acid mimetic anilides
WO1999065898A1 (en) * 1998-06-16 1999-12-23 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Imidazolyl derivatives
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
AU762423B2 (en) * 1998-07-06 2003-06-26 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors with In Vivo radiosensitizing properties
SI1094815T1 (en) 1998-07-06 2004-04-30 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
EP1107962B1 (en) * 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
CZ2001660A3 (cs) 1998-08-27 2002-05-15 Pfizer Products Inc. Alkynylsubstituované chinolin-2-ony, farmaceutické kompozice a způsoby léčení na jejich bázi a způsob výroby těchto sloučenin
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
UA71592C2 (uk) * 1998-12-23 2004-12-15 Янссен Фармацевтика Н.В. Похідні 1,2-анельованого хіноліну, спосіб їх одержання (варіанти), фармацевтична композиція, що їх містить, проміжна сполука та спосіб її одержання
AU2124800A (en) * 1999-02-11 2000-08-29 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ATE375794T1 (de) 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
JP2003525234A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
US20030027808A1 (en) * 2000-02-29 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064199A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
US20030022918A1 (en) * 2000-02-29 2003-01-30 Horak Ivan David Farnesyl protein transferase inhibitor combinations with an her2 antibody
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397256A1 (en) * 2000-02-29 2001-09-07 Mary Ellen Margaret Rybak Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
EP1263437A2 (en) * 2000-02-29 2002-12-11 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
US20030186925A1 (en) * 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
JP2003525255A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
EP1261342A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
CA2397253A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
US7173040B2 (en) * 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
US7067531B2 (en) * 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2001293826A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
AU2002214056A1 (en) * 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
ES2261523T3 (es) * 2000-11-28 2006-11-16 Janssen Pharmaceutica N.V. Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria.
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
ATE325116T1 (de) * 2000-12-27 2006-06-15 Janssen Pharmaceutica Nv Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
EP1365763B1 (en) * 2001-02-15 2008-11-26 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
EP1373255B1 (en) 2001-03-12 2005-01-26 Janssen Pharmaceutica N.V. Process for the preparation of imidazole compounds
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
WO2003051880A1 (en) 2001-12-19 2003-06-26 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
AU2003223970B2 (en) * 2002-03-22 2008-03-06 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
WO2006034003A2 (en) * 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
DK2362218T3 (en) 2004-11-05 2014-11-17 Janssen Pharmaceutica Nv Methods for monitoring the effectiveness of farnesyl transferase
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JP5331680B2 (ja) 2006-04-20 2013-10-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤
DE102007015709B4 (de) 2007-01-25 2009-09-03 Webasto Ag Fahrzeugdach
NZ581698A (en) 2007-06-05 2012-09-28 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009117484A2 (en) * 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
AU2009313927A1 (en) 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
CA2774769A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
CA2794112A1 (en) 2010-04-06 2011-10-13 Brigham Young University Antimetastatic compounds
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2806112C (en) 2010-07-28 2023-03-21 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
EP2616453A4 (en) * 2010-08-24 2014-07-02 Univ Brigham Young ANTIMETASTATIC COMPOUNDS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2013052465A1 (en) * 2011-10-02 2013-04-11 Trustees Of Boston University [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
AU2013299922B2 (en) 2012-08-07 2018-06-21 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JP6616190B2 (ja) * 2014-02-07 2019-12-04 国立大学法人 東京医科歯科大学 筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤
EP3995589A1 (en) 2015-08-17 2022-05-11 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EP3133066A1 (en) * 2015-08-21 2017-02-22 Merck Patent GmbH Hydrophilic compounds for optically active devices
US9815790B2 (en) 2015-08-27 2017-11-14 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
CA3042747A1 (en) 2016-11-03 2018-05-11 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900501A (en) * 1970-12-23 1975-08-19 Hoffmann La Roche Benzophenone intermediates for 7-lower alkanoyl benzodiazepines
IL65709A (en) * 1981-05-18 1986-01-31 Chevron Res Electroactive polymers
JPS63275548A (ja) * 1987-05-02 1988-11-14 Res Inst For Prod Dev ｏ−アミノベンゾイル化合物の製造方法
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
EP0574992A1 (en) * 1992-06-17 1993-12-22 Glaxo Group Limited 5-(1,2,4-Triazol-1-ylmethyl)-3H-isobenzofuran-1-one derivatives, their preparation and use as aromatase inhibitors
EP0677513B1 (en) * 1994-04-15 1999-08-18 Takeda Chemical Industries, Ltd. Octahydro-2-naphthalenecarboxylic acid derivative, its production and use

Also Published As

Publication number Publication date
CN1101391C (zh) 2003-02-12
DE69618999T2 (de) 2002-09-26
ZA969087B (en) 1998-04-29
EP1106610B1 (en) 2004-06-16
MY116577A (en) 2004-02-28
JP4257869B2 (ja) 2009-04-22
MX9802067A (es) 1998-08-30
NO980928D0 (no) 1998-03-04
NZ321576A (en) 1999-05-28
AU7493396A (en) 1997-05-22
IL123567A0 (en) 1998-10-30
DK1019395T3 (da) 2002-05-06
HUP9802424A3 (en) 2003-02-28
SK55698A3 (en) 1999-02-11
ATE269322T1 (de) 2004-07-15
IL123567A (en) 2002-11-10
CZ127298A3 (cs) 1998-12-16
EA199800395A1 (ru) 1998-10-29
DE69632751T2 (de) 2005-08-04
CA2231143C (en) 2005-06-21
HK1036064A1 (en) 2001-12-21
TR199800720T2 (xx) 1998-09-21
US5968952A (en) 1999-10-19
CZ290954B6 (cs) 2002-11-13
TW349948B (en) 1999-01-11
PT1019395E (pt) 2002-07-31
JPH11514635A (ja) 1999-12-14
DE69618999D1 (de) 2002-03-14
ES2233557T3 (es) 2005-06-16
AU712435B2 (en) 1999-11-04
WO1997016443A1 (en) 1997-05-09
KR19990063639A (ko) 1999-07-26
DE69632751D1 (de) 2004-07-22
KR100417620B1 (ko) 2004-05-27
HK1027576A1 (en) 2001-01-19
EP1019395B1 (en) 2002-01-30
CA2231143A1 (en) 1997-05-09
HU224032B1 (hu) 2005-05-30
AR004699A1 (es) 1999-03-10
EP1106610A1 (en) 2001-06-13
CN1200732A (zh) 1998-12-02
PL328230A1 (en) 1999-01-18
EA000719B1 (ru) 2000-02-28
EP1019395A1 (en) 2000-07-19
ES2171736T3 (es) 2002-09-16
NO980928L (no) 1998-04-29
HUP9802424A2 (hu) 1999-10-28
NO314037B1 (no) 2003-01-20
SK282642B6 (sk) 2002-10-08
ATE212627T1 (de) 2002-02-15
PL184168B1 (pl) 2002-09-30
SI1019395T1 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
CY2287B1 (en) Farnesyl transferase inhibiting 2-quinolone derivatives
IL123155A0 (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
AP9801257A0 (en) Farnesyl protein transferase inhibiting (imidazol-5-YL) methyl-2-quinoline derivatives
EP0833633A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP0862435A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP0841919A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP0817629A4 (en) FARNESYL-PROTEIN TRANSFERASE INHIBITORS
EP0763537A3 (en) Non-peptides farnesyl transfer inhibitors
IL122812A0 (en) 4,9-ethano-benzo (F) isoindole derivatives as farnesyl transferase inhibitors
HU9602516D0 (en) Isoprenyl transferase inhibitors
EP0817630A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
GB9524976D0 (en) Subsea clamp
IL130453A0 (en) Farnesyl transferase inhibitors
ZA971254B (en) Farnesyl transferase inhibitors
IL155594A0 (en) Farnesyl transferase inhibitors
SI0948483T1 (en) Farnesyl transferase inhibitors
IL141626A0 (en) Farnesyl transferase inhibitors
GB2307940B (en) Subsea clamp
ZA962433B (en) Inhibitors of farnesyl-protein transferase
EP0842291A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP0837875A4 (en) FARNESYLE TRANSFERASE INHIBITORS
EP0837857A4 (en) FARNESYL-PROTEIN TRANSFERASE INHIBITORS
GB9610174D0 (en) Prenyl transferase inhibitors
GB9519595D0 (en) Inetellectual sovereignty